Can low free testosterone and DHEA-S in postmenopausal women contribute to lower energy and difficulty maintaining lean muscle?

During the postmenopausal transition, ovarian and adrenal aging cause a progressive decline in circulating androgens, resulting in significantly lower levels of free testosterone and dehydroepiandrosterone sulfate (DHEA-S). This hormonal shift has distinct clinical implications for muscle maintenance and subjective energy.

Impact on lean muscle and mechanisms

• Anabolic impairment: Low free testosterone directly limits skeletal muscle preservation. Testosterone normally stimulates the muscle protein fractional synthesis rate (FSR) and maintains type II muscle fibers; thus, a low free testosterone state impairs baseline muscle protein synthesis.
• Intracellular conversion: DHEA-S serves as a precursor converted locally within target skeletal tissues into active androgens to modulate muscle maintenance. However, clinical trials of DHEA supplementation alone do not consistently improve muscle mass or protein synthesis, indicating its independent impact is modest.
• Estrogen deficiency: Estrogen decline is the dominant hormonal driver of postmenopausal muscle loss, directly contributing to accelerated sarcopenia, impaired mitochondrial function, and decreased satellite cell activation.

Relationship with subjective energy

• Plausible but inconsistent link: While observational and historical reports associate declining androgen levels with fatigue and diminished well-being, robust randomized controlled trials (RCTs) demonstrate that neither systemic DHEA nor physiological testosterone replacement consistently improves vitality or resolves fatigue. Consequently, major guidelines do not support using androgen levels to diagnose or treat unexplained fatigue.

Bottom line

• Postmenopausal declines in free testosterone and DHEA-S plausibly impair muscle maintenance by reducing muscle protein synthesis rates and local androgen precursor availability, alongside dominant estrogen-deficiency pathways. However, current clinical evidence does not support low androgens as a primary, rectifiable driver of subjective fatigue.